Women’s Heart Health Blood Tests: Pregnancy History, Menopause, Lipids, ApoB, Lp(a), and Cardiometabolic Risk

Quick answer: Women’s heart-health assessment should combine conventional cardiovascular factors with reproductive and life-stage history. A pregnancy complicated by preeclampsia, gestational hypertension, gestational diabetes, preterm delivery, or another adverse outcome can identify higher long-term risk. The menopause transition can coincide with less favorable lipid, blood-pressure, body-composition, and glucose patterns. A Lipid Panel Test is a common starting point; Apolipoprotein B Test, Lipoprotein (a) Test, glucose-related tests, kidney markers, and selected inflammation testing may answer additional questions. Blood work estimates risk; it does not show coronary plaque, diagnose a heart attack, or replace blood pressure, examination, ECG, imaging, or professional care.

Part of the Ulta Lab Tests Knowledge Center

This focused guide complements the broader Heart Health Blood Tests pillar, which explains conventional lipids, ApoB, Lp(a), hs-CRP, cardiometabolic markers, kidney context, treatment monitoring, and the limited roles of acute cardiac biomarkers. For foundational testing literacy, use The Complete Guide to Lab Tests and Blood Work, How to Read and Understand Your Lab Results, and Direct-Access Lab Testing: How It Works and What to Expect.

This article owns the women-specific prevention question. For active or concerning symptoms, use the separate guide to heart disease symptoms in women. For detailed inherited-risk interpretation, see what an elevated Lp(a) result means.

Key Takeaways

• Pregnancy history is part of cardiovascular history. Preeclampsia, gestational hypertension, gestational diabetes, preterm delivery, and related adverse outcomes can identify women who need earlier or more deliberate risk-factor follow-up.
• Menopause is a life-stage risk context, not a diagnosis of heart disease. Early menopause is a recognized risk enhancer, and the menopause transition can coincide with changes in cholesterol, blood pressure, body composition, and glucose regulation.
• A standard lipid panel remains foundational. ApoB estimates atherogenic particle concentration, while Lp(a) identifies a largely inherited risk factor not included in the routine lipid panel.
• Current U.S. dyslipidemia guidance supports measuring Lp(a) at least once in adulthood and using ApoB selectively when it may clarify residual or discordant risk.^{1, 2}
• Glucose, A1C, kidney markers, and selected hs-CRP testing can add context, but no single “women’s heart panel” is appropriate for everyone.
• Troponin, BNP, NT-proBNP, and MPO are not routine wellness tests for all women. Their value depends on an acute, symptom-directed, heart-failure, or specialist question.
• Normal laboratory results cannot rule out coronary disease, microvascular dysfunction, arrhythmia, valve disease, or an active emergency.

Why Women’s Heart-Risk Assessment Needs More Than a Standard Score

Traditional risk assessment considers age, cholesterol, blood pressure, diabetes, smoking, kidney health, family history, and known cardiovascular disease. Those factors matter in women and men. Women may also have sex-specific or female-predominant risk information that is easy to lose when reproductive history is not recorded.

The 2026 U.S. dyslipidemia guideline uses the PREVENT-ASCVD equations as a starting point for many primary-prevention decisions, then calls for personalization with factors that may not be fully represented in a calculator. Reproductive risk markers include early menopause, preeclampsia, and gestational diabetes. Chronic inflammatory disease, chronic kidney disease, family history, ancestry, and selected biomarkers can also change the discussion.^{1, 2}

This does not mean that every woman needs a larger panel or a lower self-selected “optimal” range. It means that the same laboratory value may carry different significance in a 35-year-old with previous severe preeclampsia, a 52-year-old entering menopause, a 68-year-old with diabetes and kidney disease, and a person with established atherosclerotic cardiovascular disease.

Pregnancy History Is Cardiovascular History

Pregnancy places substantial metabolic and vascular demands on the body. An adverse pregnancy outcome can be an early signal of susceptibility to later hypertension, diabetes, kidney disease, heart failure, stroke, or atherosclerotic cardiovascular disease. The outcome does not prove that future disease will occur, and it should not be treated as a personal failure. It is a reason to preserve the history and connect obstetric, primary-care, and cardiovascular follow-up.³

The following framework is educational and is not a diagnostic or treatment algorithm.

Pregnancy history	Why it matters later	Laboratory questions that may be reasonable	What else is essential
Preeclampsia, eclampsia, or gestational hypertension	Associated with later chronic hypertension and cardiovascular disease risk.	Current lipid and glucose status; kidney filtration and urine albumin when blood-pressure, kidney, or diabetes risk supports it.	Accurate blood-pressure follow-up, medication review, pregnancy timing, and professional assessment.
Gestational diabetes	Identifies a substantially higher lifetime risk of prediabetes and type 2 diabetes.	A protocol-specific 75-g oral glucose tolerance test in the early postpartum pathway; ongoing glucose or A1C assessment thereafter.	Current diabetes guidance recommends lifelong screening every 1–3 years, individualized to results and risk.4
Preterm delivery, placental abruption, or a small-for-gestational-age infant	May identify shared vascular, placental, inflammatory, or metabolic risk.	Right-sized assessment of lipids, glucose regulation, and kidney health based on the complete history.	Clarify gestational age, cause, recurrence, and other pregnancy complications with a healthcare professional.
Peripartum cardiomyopathy or another cardiovascular diagnosis during pregnancy	This is established cardiac disease, not merely a future risk enhancer.	Testing should follow a cardiology-led plan rather than a general prevention panel.	Cardiac imaging, medication management, pregnancy counseling, and specialist follow-up may be required.

Testing years after pregnancy should answer the woman’s current question. A remote history of preeclampsia does not make acute pregnancy tests useful now. Conversely, someone who is currently pregnant or recently postpartum needs obstetric guidance; the Pregnancy Blood Tests and Prenatal Screening guide explains why pregnancy-specific timing, thresholds, blood pressure, and clinical monitoring differ from routine adult prevention.

Menopause, Early Menopause, and Cardiometabolic Risk

Menopause is reached after 12 months without menstruation when another cause is not responsible. The preceding menopause transition can last several years. Age remains a major driver of cardiovascular risk, but research also shows that total cholesterol, LDL cholesterol, triglycerides, Lp(a), blood pressure, body composition, and metabolic-syndrome risk may change across the transition.⁵

Early menopause and premature menopause deserve specific attention because current cardiovascular guidance treats earlier loss of ovarian function as a risk-enhancing history. The exact age, whether menopause was natural or induced, prior cancer therapy or surgery, symptoms, blood pressure, tobacco exposure, and other health conditions all affect interpretation.

Menopause does not automatically justify a broad reproductive-hormone panel for cardiovascular screening. Natural menopause in the usual age range is generally identified from the menstrual history and clinical context. Hormone testing may be useful for a separate reproductive or endocrine question, which is covered in the Women’s Hormone Blood Tests guide. It should not substitute for lipids, blood pressure, glucose assessment, or overall cardiovascular-risk estimation.

Menopausal hormone therapy can be appropriate for defined menopausal indications after individualized risk-benefit discussion, but estrogen-containing therapy is not recommended solely for primary prevention of cardiovascular disease in women who experience menopause at the average age.⁶ Do not start, stop, or change hormone therapy based on this article or one laboratory result.

Core Blood Tests for Women’s Cardiovascular Risk

The most useful testing plan is the smallest set that answers a defined question. The table below separates foundational measures from selective risk refinement.

Test	Use status	What it adds	Important limitation
Lipid panel	Common or first-line	Reports total cholesterol, LDL-C, HDL-C, triglycerides, and calculated non-HDL-C for risk assessment and monitoring.	Does not include Lp(a), does not directly count atherogenic particles, and cannot show plaque.
ApoB	Risk-based or targeted	Estimates the concentration of atherogenic particles and may clarify discordance, especially with elevated triglycerides, diabetes, metabolic risk, or low treated LDL-C.	Does not identify plaque location, diagnose a heart attack, or replace the lipid panel and clinical risk assessment.
Lp(a)	Inherited-risk assessment	Identifies a largely genetic risk factor that is not included in a standard lipid panel. Current U.S. guidance supports at least one adult measurement.	It is a risk enhancer, not a diagnosis. Units are not universally convertible, and routine repeat testing is often unnecessary.
A1c Test	Common when screening or monitoring is appropriate	Reflects average glucose exposure over roughly two to three months and helps identify glycemic risk.	Pregnancy, anemia, altered red-cell turnover, hemoglobin variants, kidney disease, and other factors can affect interpretation.
Glucose Test	Common when screening or diagnostic support is appropriate	Provides a point-in-time glucose measurement; fasting status can make the result more standardized.	Recent food, stress, illness, medicines, and collection timing matter. One result may require confirmation.
hs-CRP Test	Selective risk refinement	May add inflammatory context when a stable adult’s cardiovascular-risk decision remains uncertain.	Nonspecific. Infection, injury, dental disease, autoimmune activity, pregnancy, and other inflammation can raise it.
Comprehensive Metabolic Panel Test - CMP	Risk-based or targeted	Provides glucose, electrolyte, kidney, liver, and protein context that may matter with medications or comorbid conditions.	It is not a dedicated heart test and can create incidental findings when ordered without a defined question.
Albumin Random Urine Test with Creatinine	Risk-based cardiorenal assessment	Supports calculation of the urine albumin-to-creatinine ratio, or uACR, especially with diabetes, hypertension, or kidney risk.	Exercise, fever, infection, menstruation, marked hyperglycemia, and temporary physiologic changes can affect the result. Persistence matters.7
TSH Test	Selected symptom or secondary-cause assessment	May help when thyroid dysfunction is a plausible contributor to lipid changes, weight change, or palpitations.	Not a universal heart screen. Pregnancy, illness, medicines, supplements, pituitary disease, and timing can affect interpretation.

Lipid Panel vs. ApoB vs. Lp(a): Three Different Questions

Measurement	Primary question	When it may add value	What it cannot establish
LDL-C and non-HDL-C from a lipid panel	How much cholesterol is carried in LDL or all non-HDL atherogenic particles?	Foundational risk assessment and treatment monitoring.	The exact number of particles, inherited Lp(a) burden, or the presence and location of plaque.
ApoB	How many major atherogenic particles are circulating?	When cholesterol mass and particle number may be discordant.	Which artery is affected, whether plaque is obstructive, or whether an acute event is occurring.
Lp(a)	Is a largely inherited Lp(a)-related risk factor present?	At least once in adulthood and when family or premature cardiovascular history raises concern.	Current plaque burden, a guaranteed future event, or a treatment decision by itself.

The most useful next step is not to chase every number toward a single internet target. It is to ask whether LDL-C, non-HDL-C, triglycerides, ApoB, and Lp(a) form a coherent pattern and whether that pattern changes the overall prevention discussion. For example, current guidance identifies Lp(a) at or above 125 nmol/L or 50 mg/dL as a risk-enhancing level, but those values are decision points—not interchangeable units, proof of disease, or universal treatment targets.²

Cardiometabolic and Kidney Risk Must Be Read With Lipids

Cardiovascular risk is not a cholesterol-only problem. Blood pressure, glucose regulation, body composition, kidney health, sleep, tobacco exposure, physical activity, medications, and inflammatory disease can interact with lipid-related risk. Women with previous gestational diabetes, current prediabetes or diabetes, high triglycerides, central weight gain, chronic kidney disease, or hypertension may need a broader but still focused assessment. The Hypertension Lab Tests guide explains which laboratory tests may help identify associated conditions or treatment considerations while emphasizing that blood pressure itself is measured with a validated device, not a blood test.

Glucose and A1C

A1C and glucose are complementary. A1C summarizes longer-term exposure, while fasting glucose records one standardized point. Neither should be averaged with the other when results disagree. The Diabetes and Prediabetes Blood Tests guide owns diagnostic thresholds, confirmation, oral glucose tolerance testing, and monitoring details. Women with weight-related metabolic risk can also use the Metabolic Health Blood Tests guide.

Kidney function and urine albumin

Blood creatinine and estimated filtration describe kidney filtration; urine albumin identifies a different type of kidney and vascular injury. These measurements are especially relevant with diabetes, hypertension, previous hypertensive pregnancy disorders, known kidney disease, or medications that require renal context. One abnormal value does not automatically establish chronic kidney disease. The Kidney Function Tests guide explains filtration, uACR, confirmation, and trends.

Inflammation

High-sensitivity CRP can refine risk in selected, clinically stable adults, but it does not identify the source of inflammation. A transient elevation during infection, injury, surgery, dental inflammation, or autoimmune activity should not be treated as proof of vascular disease. Repetition after recovery may be more useful when the result would change a decision.

Troponin, BNP, NT-proBNP, and MPO Are Not Routine Prevention Tests

The previous version of this article placed acute and specialized biomarkers inside broad women’s prevention panels. That approach has been removed. These tests answer different clinical questions:

Test	Appropriate clinical question	Why it is not a routine wellness screen
Troponin T High Sensitivity Test	Could current symptoms and other findings represent heart-muscle injury?	Acute interpretation depends on symptom timing, serial change, assay-specific thresholds, ECG findings, and clinical probability. An outpatient result cannot make chest pain safe.8
BNP Test or NT-proBNP Test	Could breathlessness, swelling, fatigue, or another presentation reflect heart failure or cardiac wall stress?	Age, kidney function, rhythm, body size, medicines, and other conditions affect results. Evaluation usually requires examination and cardiac testing.9
Cardio IQ Myeloperoxidase Test	Is a specialist evaluating a narrowly defined vascular-inflammation question?	Current major prevention guidance does not establish MPO as a universal screening test, and an abnormal result does not diagnose plaque or microvascular disease.

A larger panel is not automatically more precise. Unfocused testing increases the chance of incidental findings, biological variation, false-positive interpretation, anxiety, cost, and unnecessary follow-up. Every test should have a question and a plan for what happens after the result.

What Blood Tests Can—and Cannot—Reveal

Blood tests may help reveal	Blood tests cannot establish by themselves
Conventional cholesterol and triglyceride patterns	Whether a coronary artery is narrowed or where plaque is located
Atherogenic particle burden estimated by ApoB	Whether chest discomfort is cardiac, gastrointestinal, muscular, or another cause
Inherited Lp(a)-related risk	Heart rhythm, valve structure, pumping function, or exercise capacity
Glucose, kidney, and selected inflammatory context	Coronary microvascular dysfunction, which requires symptom-led cardiac evaluation
Comparable trends after an intervention or treatment	Which medication, dose, imaging study, or procedure is appropriate for an individual

Depending on the question, a complete assessment may also require accurate blood-pressure measurements, physical examination, ECG, rhythm monitoring, coronary artery calcium scoring, echocardiography, stress testing, vascular imaging, or specialist evaluation. A favorable laboratory profile does not guarantee that the heart and blood vessels are free of disease.

When to Consider Discussing Women’s Heart-Health Testing

A focused testing discussion may be useful when a woman:

• Has not had recent age- and risk-appropriate lipid or glucose assessment.
• Had preeclampsia, eclampsia, gestational hypertension, gestational diabetes, preterm delivery, placental abruption, or another adverse pregnancy outcome.
• Experienced early or premature menopause, surgical menopause, or menopause after cancer treatment.
• Has a first-degree relative with premature heart attack, stroke, very high cholesterol, or known elevated Lp(a).
• Has diabetes, prediabetes, hypertension, kidney disease, high triglycerides, metabolic syndrome, or a chronic inflammatory condition.
• Uses a medication that requires lipid, glucose, kidney, liver, or other safety monitoring.
• Has a previous abnormal result that needs confirmation or trend assessment.

Testing frequency should follow the purpose, the prior result, the woman’s age and risk, current guidelines, pregnancy status, and any treatment plan. “Every six months” or “every year” is not a universal schedule for every marker. Lp(a), for example, is often measured once, while modifiable lipids or glucose may be repeated when the result could change management.

A Right-Sized Testing Framework

Educational framework—not a diagnostic or treatment algorithm.

1. Start with history. Record pregnancy complications, age and type of menopause, family history, inflammatory disease, kidney disease, diabetes, cancer treatment, smoking exposure, medications, and prior cardiovascular events.
2. Confirm nonlaboratory essentials. Use accurate blood pressure, symptoms, examination findings, and a validated risk estimate when appropriate.
3. Build the foundation. Use a current lipid panel and age- or risk-appropriate glycemic assessment. Add kidney testing when history supports it.
4. Refine only when useful. Consider Lp(a) at least once in adulthood, ApoB when particle discordance or residual risk is plausible, and hs-CRP when a stable result could change a prevention discussion.
5. Avoid acute markers for wellness. Reserve troponin and natriuretic peptides for the appropriate urgent, symptom-directed, or heart-failure pathway.
6. Plan the next step before ordering. Decide whether an abnormal or discordant result would lead to confirmation, professional review, imaging, medication discussion, or no immediate change.

Preparation and Factors That Can Change Results

Factor	Tests commonly affected	Practical guidance
Fasting and recent food	Triglycerides and glucose; some order-specific panels	Follow the exact instructions attached to the order. Do not assume all lipid testing requires fasting or that all testing can be nonfasting.
Acute illness, injury, or surgery	hs-CRP, glucose, lipids, kidney markers, and other analytes	If the question is long-term risk, ask whether testing should wait until recovery.
Strenuous exercise	Inflammation, muscle, kidney, urine albumin, and selected metabolic markers	Disclose recent intense activity and follow any test-specific restriction.
Pregnancy, postpartum status, and menstruation	Glucose, kidney measures, urine albumin, inflammation markers, lipids, and hormones	Use pregnancy- or postpartum-specific clinical pathways when relevant; note menstruation during urine collection.
Medications, hormones, and supplements	Lipids, glucose, TSH, kidney and liver markers, and assay-dependent results	Provide a complete list. Do not stop a prescription, hormone, or supplement unless the prescribing professional directs it.
Hydration, alcohol, and collection timing	Triglycerides, glucose, kidney markers, and concentration-dependent results	For trend monitoring, use reasonably comparable conditions and document meaningful differences.

How to Understand Your Results

1. Confirm the exact test and units. Lp(a) reported in nmol/L is not directly interchangeable with mg/dL, and assay methods may differ.
2. Separate a laboratory reference interval from a clinical decision threshold. A report flag compares a value with that laboratory’s interval. A risk-enhancing threshold or treatment goal answers a different question.
3. Read related markers together. LDL-C, non-HDL-C, triglycerides, ApoB, and Lp(a) overlap but are not substitutes for one another.
4. Review collection conditions. Fasting, illness, exercise, pregnancy, medicines, hormones, supplements, and hydration may explain part of a change.
5. Compare appropriate trends. Use the same test, units, and reasonably similar conditions when possible. A small change may reflect biological or analytical variation.
6. Ask whether confirmation is needed. An unexpected, borderline, or discordant result may need repetition or a different test before a major conclusion.
7. Put the result back into the whole risk picture. Pregnancy history, menopause, age, blood pressure, diabetes, kidney disease, family history, tobacco exposure, symptoms, and prior cardiovascular disease all matter.

For a detailed method, use How to Read and Understand Your Lab Results.

When Symptoms Need Urgent Care

Call emergency services for new or severe chest pressure or pain; pain spreading to the arm, back, neck, jaw, or stomach; marked shortness of breath; fainting; cold sweat; sudden nausea with other concerning symptoms; sudden weakness or numbness; facial droop; difficulty speaking; or another possible heart-attack or stroke symptom. Women may also experience unusual fatigue, breathlessness, nausea, back or jaw discomfort, or symptoms that do not match a stereotypical “crushing chest pain” description.

Pregnant or postpartum patients with chest pain, severe shortness of breath, fainting, severe headache, vision changes, seizures, rapidly worsening swelling, or very high blood pressure need urgent obstetric or emergency evaluation. Do not wait for routine outpatient blood work or use a single troponin result to decide that symptoms are safe.

Questions to Ask a Healthcare Professional

• Does my pregnancy history change how you assess my lifetime cardiovascular risk?
• Was my menopause early or premature, and does that change prevention decisions?
• Which conventional risk factors are already included in my PREVENT-ASCVD estimate, and which risk enhancers need separate consideration?
• Would ApoB add information beyond my LDL-C and non-HDL-C?
• Have I had Lp(a) measured at least once, and are the reported units clear?
• Do I need diabetes follow-up because of previous gestational diabetes?
• Should kidney filtration and uACR be assessed because of hypertension, diabetes, or pregnancy history?
• Would hs-CRP change a decision, and am I clinically stable enough for a useful result?
• Could thyroid disease, medication, hormone therapy, or another condition be affecting my lipid pattern?
• Would imaging or cardiac testing answer a question that blood work cannot?
• Which results should be repeated, and under what collection conditions?
• What symptoms should prompt urgent rather than routine follow-up?

How Ulta Lab Tests May Help

Where available, Ulta Lab Tests allows patients to review individual laboratory tests online, see the listed self-pay price before ordering, complete the required collection process, and receive results through an online account. Direct access can make it easier to obtain objective information for a professional conversation, but it does not replace emergency care, an examination, diagnosis, imaging, medication management, pregnancy care, or individualized prevention planning. Review the direct-access laboratory testing guide before selecting, preparing for, or following up on testing.

Related testing areas include Heart & Cardiovascular Tests, Women’s Health Tests, Diabetes Tests, Weight Management Tests, and Kidney Tests.

Frequently Asked Questions

What blood tests are most useful for women’s heart health?

A standard lipid panel and age- or risk-appropriate glucose assessment are common starting points. Current guidance supports at least one adult Lp(a) measurement. ApoB may clarify risk when triglycerides are elevated, diabetes or metabolic risk is present, or LDL-C and particle burden may be discordant. Kidney markers and hs-CRP are selective rather than universal. The right set depends on pregnancy history, menopause, blood pressure, family history, medications, symptoms, and previous results.

Does preeclampsia increase later heart-disease risk?

Yes. Preeclampsia and other hypertensive pregnancy disorders are associated with higher long-term risk of chronic hypertension and cardiovascular disease. The history does not prove that disease is present now. It should prompt documentation, accurate blood-pressure follow-up, and a focused review of lipids, glucose, kidney health, and other risk factors with a qualified healthcare professional.

What follow-up is recommended after gestational diabetes?

Current diabetes guidance uses a protocol-specific 75-g oral glucose tolerance test in the early postpartum period and recommends lifelong screening for prediabetes or type 2 diabetes every 1–3 years after gestational diabetes. The exact test and timing depend on how long it has been since pregnancy, previous results, current pregnancy status, medicines, and other risks. A1C can be less reliable in some postpartum and blood-related settings.

Does menopause cause high cholesterol?

Age, genetics, body composition, lifestyle, medicines, and medical conditions all affect cholesterol. The menopause transition can coincide with less favorable total cholesterol, LDL-C, triglyceride, Lp(a), blood-pressure, and metabolic patterns. Menopause therefore creates a useful time to reassess overall cardiovascular risk, but one lipid change does not prove that menopause is the only cause.

Do I need hormone tests to assess heart risk after menopause?

Usually not as the primary cardiovascular assessment. Menopause is generally established from menstrual history and clinical context, and reproductive hormone levels do not replace lipid, blood-pressure, glucose, kidney, and overall risk assessment. Hormone testing may be appropriate for a separate endocrine, reproductive, or treatment question. Menopausal hormone therapy should be individualized and is not prescribed solely from a hormone value or for cardiovascular prevention.

Is ApoB more important than LDL cholesterol?

They answer related but different questions. LDL-C estimates cholesterol carried in LDL-related particles; ApoB estimates the concentration of atherogenic particles. ApoB may be especially useful when the two appear discordant, such as with elevated triglycerides, diabetes, metabolic risk, or low treated LDL-C. Neither result shows where plaque is located or independently determines treatment.

Should every woman have an Lp(a) test?

The 2026 U.S. dyslipidemia guideline recommends measuring Lp(a) at least once in adulthood. It is particularly informative when there is premature cardiovascular disease in the family, familial hypercholesterolemia, or unexplained risk. Lp(a) is largely inherited and often stable, so repeated testing is usually unnecessary unless a clinician identifies a reason. Interpret the exact reported unit rather than using a fixed conversion.

Can normal cholesterol rule out heart disease in women?

No. A normal lipid panel does not show plaque, microvascular dysfunction, heart rhythm, valve structure, blood pressure, or pumping function. It also does not include Lp(a). Symptoms, family and pregnancy history, menopause, blood pressure, diabetes, kidney health, tobacco exposure, examination, and sometimes cardiac imaging or functional testing may be needed.

Should troponin or BNP be part of a preventive heart panel?

No, not as universal wellness screening. Troponin belongs in an acute myocardial-injury pathway that uses symptoms, timing, serial measurements, ECG findings, and clinical evaluation. BNP and NT-proBNP are used when heart failure or cardiac wall stress is a defined clinical question. A normal outpatient result must not be used to delay emergency care.

How often should women repeat heart-health blood tests?

There is no single schedule for every woman or every marker. Timing depends on age, baseline values, pregnancy history, menopause, diabetes, hypertension, kidney disease, medication use, treatment changes, and whether the result would change a decision. Lp(a) is often measured once, while modifiable lipids, glucose, or kidney markers may be repeated at clinically meaningful intervals.

The Bottom Line

Women’s heart health blood tests are most useful when they connect life history with current biology. Pregnancy complications and early menopause can change the meaning of a conventional risk estimate. A lipid panel provides the foundation; ApoB may clarify particle burden, Lp(a) identifies inherited risk, and focused glucose, kidney, thyroid, or inflammation testing may add context when the history supports it.

The goal is not the largest panel or a set of universal “optimal” numbers. It is a right-sized assessment that can support an informed conversation about prevention, confirmation, monitoring, imaging, or follow-up. Review results with a qualified healthcare professional, and seek urgent care for new or severe cardiovascular or postpartum warning symptoms.

Medical References

1. American Heart Association and American College of Cardiology. 2026 Guideline on the Management of Dyslipidemia. Updated March 13, 2026.
2. American Heart Association. Top Things to Know: 2026 Guideline on the Management of Dyslipidemia. March 13, 2026.
3. Lewey J, Beckie TM, Brown HL, et al. Opportunities in the Postpartum Period to Reduce Cardiovascular Disease Risk After Adverse Pregnancy Outcomes. Circulation. 2024;149:e330-e346.
4. American Diabetes Association Professional Practice Committee. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
5. El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention. Circulation. 2020;142:e506-e532.
6. The Menopause Society. Statement on Hormone Therapy Misinformation. September 2024.
7. Kidney Disease: Improving Global Outcomes. Executive Summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024.
8. American College of Cardiology. 2021 AHA/ACC Chest Pain Guideline Perspectives. October 28, 2021.
9. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145:e895-e1032.

Educational and Disclosure

This article is educational and does not provide individual diagnosis or treatment. Laboratory results should be interpreted with symptoms, history, medications, pregnancy status, examination findings, blood pressure, and other testing when appropriate. Do not start, stop, or change a prescription medication, hormone, or supplement based on this article or one result.

Ulta Lab Tests offers laboratory-testing services and may link to tests or panels discussed on this page. This content is educational and does not provide individual diagnosis or treatment.

Update history: Originally published: December 8, 2025 | Substantively rewritten August 28, 2026, to replace provocative guideline framing, update women-specific panels and universal “optimal” targets, distinguish preventive from acute cardiac testing, add pregnancy-history and menopause context, and align lipid guidance with the 2026 U.S. dyslipidemia guideline.